Kantonsspital St.Gallen
anmelden

Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases

N De Gregorio, A De Gregorio, F Ebner, T W P Friedl, Jens Huober, R Hefty, M Wittau, W Janni & P Widschwendter

Kurzfassung

BACKGROUND
Pelvic exenterations are a last resort procedure for advanced gynecologic malignancies with elevated risks in terms of patients' morbidity.

METHODS
This single-center analysis reports surgical details, outcome and survival of all patients treated with exenteration for non-ovarian gynecologic malignancies at our university hospital during a 13-year time period. We collected data regarding patients and tumor characteristics, surgical procedures, peri- and postoperative management, transfusions, complications, and analyzed the impact on survival outcomes.

RESULTS
We identified 37 patients between 2005 and 2013 with primary or relapsed cervical cancer (59.5%), vulvar cancer (24.3%) or endometrial cancer (16.2%). Median age was 60 years and most patients (73%) had squamous cell carcinomas. Median progression-free survival was 26.2 months and median overall survival was 49.9 months. The 5-year survival rates were 34.4% for progression-free survival and 46.4% for overall survival. There were no significant differences in progression-free survival and overall survival with regard to disease entity. Patients with tumor at the resection margins (R1) had a nearly significantly worse progression-free survival (median: 28.5 vs. 7.3 months, HR 2.59, 95% CI 0.98-6.88, p = 0.056) and a significantly worse overall survival (median: not reached vs. 10.9 months, HR 4.04, 95% CI 1.40-11.64, p = 0.010) compared to patients with complete tumor resection (R0). In addition, patients without lymphovascular space invasion had a significantly better progression-free survival (p = 0.017) and overall survival (p = 0.034) then patients with lymphovascular space invasion. We observed complications in 14 patients (37.8%), 10 of those were classified as Clavien-Dindo 3 or 4. There was a trend to worse progression-free survival in patients that suffered complications (p = 0.052). Median total amount of transfused blood products was 4 (range 0-20).

CONCLUSION
Pelvic exenteration is a procedure that provides substantial progression-free survival and overall survival improvement and-in selected patients-can even achieve cure in otherwise hopeless clinical situations. Patients need to be offered earnest counseling for sufficient informed consent with realistic expectations what to expect.
   
Zitation de Gregorio N, de Gregorio A, Ebner F, Friedl T W P, Huober J, Hefty R, Wittau M, Janni W, Widschwendter P. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet 2019; 300:161-168.
   
Typ Wissenschaftlicher Artikel/Review (Englisch)
Veröffentlichungsdatum 22-04-2019
Titel der Zeitschrift Arch Gynecol Obstet (300/1)
ISSN electronic 1432-0711
Seiten 161-168
PubMed 31011878
DOI 10.1007/s00404-019-05154-4